Q1 FY27 Results: Revenue up 36% YoY, PAT up 44%, EBITDA grows 87%

Revenue Growth 20pctPat Growth 25pctEbitda Margin ExpansionEmphasis Of MatterResults View source PDF

SENORES · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

-4.3%1-day move

₹1388.00

prior close

₹1440.40

base price

In-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

-2.4-2.5——-4.3—————————

Up moveDown movePending

AI summary

Senores Pharmaceuticals reported Q1 FY27 consolidated revenue of Rs 180.21 crores, up 36% YoY from Rs 132.56 crores. Net profit rose about 44% YoY to Rs 30.45 crores. EBITDA grew 87% to Rs 54 crores with roughly 800 bps margin expansion. Regulated Markets revenue jumped 42% YoY, Emerging Markets up 30% YoY. Standalone PAT was Rs 1.03 crores. Board appointed Ms Anjali Shah as Senior Management Personnel. Auditor issued clean limited review with an emphasis of matter on estimated tax provisions in standalone results.

Likely market impact

Strong Q1 with broad-based growth and sharp margin expansion signals positive momentum. Stock may react positively to better-than-expected results.